Botulinum Toxin

Publication Date	April 2009
Publisher	Global Industry Analysts
Product Type	Report
Pages	177
ISBN Number	not applicable
Product Code	GIA00068

Buy this product or for assistance call +44 20 7060 7474

PDF £2,375.00$3951 | €2658

PRINT £2,375.00$3951 | €2658

FAX Order above formats by FAX

Summary

This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The Study Analyzes the Market for 'Botulinum Toxin' by the Following Segments: Cosmetic, and Therapeutic (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity) The report provides separate comprehensive analytics for the USA, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 19 companies including many key and niche players worldwide such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Metabiologics Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Content

I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Product Definitions and Scope of Study
- Cosmetic Applications
- Therapeutic Applications
II. Executive Summary
- 1.Industry Overview
  - A Prelude
  - Botulinum Toxin: "The Science, The Hopes & the Risks"
  - Future Opportunities Span beyond The Developed Markets
  - A Peek into Noteworthy Trends & Issues
  - Changing Consumer Sentiments
  - Aging Population: A Weighty Demographic Driver
  - Unmet Medical Needs Encourage off-Label Use: A Cause for Concern or Jubilation?
  - Need for Physician Education Rises with Growing off Label Usage
  - High Voltage Ad Campaigns Boost Patient Awareness
  - Societal Pressure to Look Young Drives up Demand for Facial Aesthetics
  - Cosmetic Botulinum Toxin to Feel the Pinch of the Recession
  - Financing of Non-Reimbursed Healthcare: The Need of the Hour
  - Combination Therapies: A Double Whammy Success
  - Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments
  - Consolidation Blows in the Aesthetic Healthcare Industry
  - Undesirable Side Effects: A Challenge to Reckon with
  - Immunogenicity Undermines Patient Compliance
  - Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo
  - Non-Injectable Alternatives to Turn on the Heat
  - Fears of Terrorism & Biological Warfare Thwart International Trade
  - Competition
  - Allergan Wields the Scepter
  - Reloxin Emerges to Threaten Allergan's Dominance
  - Reloxin vs Botox: A Comparison
  - Outlook for Allergan's Botox
  - Market Share Statistics: The New Batting Order
  - Global
  - Europe
  - United States
  - Market Share Statistics: through the Looking Glass: Year 2012
  - Global
  - United States
  - Europe
  - A Peek into Products Approved & in Pipeline
  - New Treatment Indications for Botulinum Toxin Compounds/Brands in Pipeline as of the Year 2008
  - List of Botulinum Toxin Products/Brands that are Approved for Various Cosmetic Therapeutic Indications as of the Year 2007
- 2.Product Overview
  - Botulinum Toxin: A Poison That Cures
  - Structure & Mechanism of Action
  - Disadvantages
  - Classification of Botulinum Toxin
  - Botulinum Toxin Type A
  - Historical Timeline of Botulinum Toxin: 1885-2002
  - Botox
  - Key Characteristics of Botox and Botox Cosmetic
  - Approvals and Indications of Botox in Select Regions
  - Common Adverse Reactions with Botox
  - Dysport/ Reloxin
  - Key Characteristics of Dysport
  - PurTox
  - Key Characteristics of PurTox
  - Xeomin/ NT-201
  - Key Characteristics of Xeomin/ NT-201
  - Botulinum Toxin Type B
  - Myobloc/NeuroBloc
  - Key Characteristics of Myobloc
  - Applications of Botulinum Toxin
  - Cosmetic Applications
  - Glabellar Lines
  - Facial Wrinkles
  - Key Cosmetic Indications for Botulinum Toxin
  - Therapeutic Applications
  - Movement Disorders/Pain
  - Cervical Dystonia
  - Hemifacial Spasm
  - Blepharospasm
  - Strabismus
  - Chronic Pain
  - Botox in Migraine Treatment
  - Hyperhidrosis
  - Bladder Dysfunctions
  - Spasticity
  - Other Applications
- 3.Recent Industry Activity
  - Johnson & Johnson Acquires Mentor Corporation
  - Azzalure Gains Approval from 15 European Countries
  - Inclusion of New Side Effect in Botox and Botox Cosmetic Labels
  - Azzalure Gains Approval for Aesthetic Application in the UK
  - BioForm Medical Acquires Advanced Cosmetic Intervention
  - Galderma to Acquire CollaGenex
  - Allergan and Clinique Form Strategic Collaboration
  - Ipsen and Medicis File BLA for Reloxin
  - Allergan and Clinique Launch New Skin Care Products
  - FDA Accepts Ipsen's Filing for Reloxin
  - GlaxoSmithKline Gains Approval for BOTOX in Japan
  - Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product
  - Allergan Commences Botox Study for Urological Cases in India
  - FDA Accepts BLA Filing for Dysport in Cervical Dystonia Cases
  - Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX
  - Allergan to Set up a New Subsidiary in India
  - Allergan Join Hands with India-Based Kaya
  - Q-Med and Medy-Tox Cancel the Collaboration Agreement
  - Galderma to Increase Awareness in Brazil
  - Allergan to Launch New Products in India
  - Allergan to Establish a State-of-the-Art Botox Training Institute
  - Q-Med Inks a Distribution Agreement with Medy -Tox
  - Q-Med Collaborates with Medy-Tox for a Range of Joint Activities
  - Medicis Plans Investment in Revance
  - Galderma Receives Distribution Rights for Dysport (R)
  - Allergan to Acquire Espirit Pharma
  - Allergan Launches "Project: Sweat Free"
  - Solstice Neurosciences Inks Commercialization Agreement
  - Ipsen Partners with Galderma
  - Bio-Med Unveils BOTOGenie
  - Medicis Launches PERLANE
  - Studies Underway for Botulinum Toxin Usage for Enlarged Calf Muscles
  - FDA to Assess Reloxin for Cosmetic Use
  - Ipsen Inks Development and Distribution Agreement with Medicis
  - Allergan Rolls out New Division with Acquisition of Inamed
  - FTC Mandates Allergan Divest Rights to Reloxin
  - Medicis Inks Agreement with Ipsen
  - Solstice Neurosciences Inks Licensing Agreement with DreamPharma
  - Botox Enters India Market
  - Mentor Begins Phase-I Clinical Trial on Botulinum Toxin
  - Allergan Inks Agreement with GlaxoSmithKline
  - DOR BioPharma Inks Agreement with Dowpharma
  - Merz Pharma Receives Approval for Botulinum Toxin Type A
  - Mentor Initiates Phase-I Clinical Trial
  - Mentor Establishes New Production Facility
  - DOR BioPharma and Thomas Jefferson University Teams-up with US Army
  - Mentor Inks Licensing Agreement with WARF
  - Solstice Acquires World Rights for Myobloc
  - Inamed Rolls out Reloxin Brand
- 4.Focus on Select Key Players
  - Allergan, Inc (USA)
  - Ipsen Group (France)
  - Lanzhou Institute of Biological Products (China)
  - Metabiologics Inc, (USA)
  - Merz Pharmaceuticals GmbH (Germany)
  - Mentor Corporation (USA)
  - Medy-Tox Incorporated (South Korea)
  - Medicis Pharmaceutical Corporation (USA)
  - Solstice Neurosciences, Inc. (USA)
- 5.Global Market Perspective
III. Market
- 1.The United States
  - A. Market Analysis
    - Outlook
    - Cosmetic Procedures: An Overview
    - Botox Leads the US Botulinum Toxin Market
    - Botox Approvals and Indications in the US
    - Market Dynamics
    - Booming Non-Surgical Treatments
    - Aging Baby Boomers Drive Aesthetic Business
    - Expanding Physician Base Extends Impetus to Growth
    - Demand for Professional Help on the Rise
    - Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin
    - Medical Spas - Growing in Number
    - Botulism Poisoning: A Major Concern
    - Botox Injection - Popular Non-Invasive Cosmetic Procedure
    - Botox Attracts American Men
    - US Cosmetic Market - Statistical Data
    - Strategic Corporate Developments
    - Key Players
  - B. Market Analytics
- 2.Europe
  - A. Market Analysis
    - Outlook
    - European Market - A Primer
    - Botox Approvals and Indications in Select European Countries
    - Botox to Support Radiation Treatments
    - Strategic Corporate Developments
    - Key Players
  - B. Market Analytics
- 3.Rest of World
  - A. Market Analysis
    - Outlook
    - Asia
    - India - An Emerging Market for Botox
    - South Korea
    - Australia - A Well Supported Market
    - Botox Approvals and Indications in Select Asian Countries
    - Botox Approvals and Indications in Select Latin American Regions
    - Botox Approvals and Indications in Other Select Global Regions
    - Strategic Corporate Developments
    - Key Players
  - B. Market Analytics
IV. Competitive Landscape
List of Tables
- Table 1: Revenues of Allergan, Inc (2006 & 2007): Breakdown of Net Sales of Botox/Neuromodulator and Total Revenues (in US$ Million)
- Table 2: European Market for Non-Surgical Cosmetic Procedures (2006): Percentage Share Breakdown of Revenues by Leading Players -Allergan, Q-Med, Mentor Corporation, Mattioli Engineering, Candela, and Others (includes corresponding Graph/Chart)
- Table 3: European Market for Non-Surgical Cosmetic Procedures (2009): Percentage Breakdown of Revenues by Type of Procedure -Cosmetic Botulinum Toxin Injections, Facial Fillers, Microdermabrasion, Chemical Peeling, and Aesthetic Lasers (includes corresponding Graph/Chart)
- Table 4: World Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand -Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), and Others (includes corresponding Graph/Chart)
- Table 5: World Market for Cosmetic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand -Botox/Vistabel (Allergan) and Dysport/Reloxin (Ipsen/Medicis)
- Table 6: European Market for Cosmetic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand -Botox/Vistabel (Allergan) and Dysport (Ipsen)
- Table 7: European Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/Brand -Botox (Allergan), Dysport (Ispen), and Others (includes corresponding Graph/Chart)
- Table 8: US Market for Therapeutic Neurotoxins (2008): Percentage Breakdown of Revenues by Company/ Brand -Botox (Allergan) and Myobloc (Solstice)
- Table 9: World Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/ Brand -Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), Puretox (Mentor), Xeomin (Merz), and Others (includes corresponding Graph/Chart)
- Table 10: World Market for Cosmetic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand -Botox (Allergan), Dysport/Reloxin (Ipsen/Medicis), Xeomin (Merz), and Puretox (Mentor) (includes corresponding Graph/Chart)
- Table 11: US Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand -Botox (Allergan), Myobloc (Solstice), Dysport (Ispen), Puretox (Mentor) and Xeomin (Merz) (includes corresponding Graph/Chart)
- Table 12: US Market for Cosmetic Neurotoxins (2008 & 2012P): Percentage Breakdown of Revenues by Company/ Brand -Botox (Allergan), Reloxin (Medicis), and Puretox (Mentor) (includes corresponding Graph/Chart)
- Table 13: European Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand -Botox (Allergan), Dysport (Ispen), Xeomin (Merz) and Neurobloc (Solstice) (includes corresponding Graph/Chart)
- Table 14: World Recent past, Current & Future Analysis for Botulinum Toxin by Geographic Region/Country - US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 15: World 10-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 16: World Recent past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 17: World 10-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 18: World Recent past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Europe and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 19: World 10-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 20: Global Recent past, Current & Future Analysis for Botulinum Toxin in Therapeutic Application by Disease Indication - Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 21: World 10-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication - Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 22: Number of Botox Injections (2000-2005) (includes corresponding Graph/Chart)
- Table 23: Botox Injections by Gender (2004)
- Table 24: Botox Injections by Age Group (2004) (includes corresponding Graph/Chart)
- Table 25: Non-Invasive Cosmetic Procedures in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices (includes corresponding Graph/Chart)
- Table 26: Cosmetic Procedures (Surgical/ Non-Surgical) in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices
- Table 27: Cosmetic Market in the US (2004 & 2005): Leading Surgical Procedures (includes corresponding Graph/Chart)
- Table 28: Cosmetic Market in the US (2004 & 2005): Leading Non-Surgical Procedures (includes corresponding Graph/Chart)
- Table 29: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Gender
- Table 30: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Age Group (includes corresponding Graph/Chart)
- Table 31: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Facility (includes corresponding Graph/Chart)
- Table 32: Cosmetic Market in the US (2004): Percentage Breakdown by Procedure Type
- Table 33: US Recent past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 34: US 10-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 35: European Recent past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 36: European 10-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
- Table 37: Leading Players in the Korean Botulinum Toxin Market (2008): Percentage Breakdown of Sales for Medy-Tox, Allergan, Ipsen, and Lanzhou Institute (includes corresponding Graph/Chart)
- Table 38: Rest of World Recent past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 39: Rest of World 10-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, and Spasticity) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)